Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
(1) The three-year results of a clinical trial confirm that raloxifene is the second-line treatment for primary and secondary prevention of vertebral fracture in postmenopausal women at risk of osteoporosis.  They also confirm that raloxifene increases the risks of thromboembolism and diabetes.
D001943:Breast Neoplasms / Q000139:chemically induced; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003920:Diabetes Mellitus / Q000139:chemically induced; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D016103:Spinal Fractures / Q000517:prevention & control*; D013923:Thromboembolism / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000139:chemically induced
D020849:Raloxifene Hydrochloride